Affected by lockdowns and the resulting postponement of patient visits to the doctor, Ferinject and Veltassa reported sales declines in H1. However, the nephrology portfolio showed resilience on the back of its ‘essential’ dialysis business. Moreover, higher other income and strict cost management ensured a steady increase in EBITDA. As confinement measures ease, business should be back on track in H2. In the mid-term, new product launches, particularly in the nephrology portfolio
07 Aug 2020
Nephrology shows resilience as other businesses bear the COVID-19 brunt
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Nephrology shows resilience as other businesses bear the COVID-19 brunt
- Published:
07 Aug 2020 -
Author:
Sumit Sayal -
Pages:
4
Affected by lockdowns and the resulting postponement of patient visits to the doctor, Ferinject and Veltassa reported sales declines in H1. However, the nephrology portfolio showed resilience on the back of its ‘essential’ dialysis business. Moreover, higher other income and strict cost management ensured a steady increase in EBITDA. As confinement measures ease, business should be back on track in H2. In the mid-term, new product launches, particularly in the nephrology portfolio